SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending due to the successful orbital launch and separation of its BlueBird 6 satellite, marking a significant advancement for its direct-to-device cellular broadband network. The community, dubbed "spacemob," is highly enthusiastic, anticipating substantial long-term growth and a potential short squeeze as the company progresses in connecting the unconnected.

Starfighters Space Inc

Starfighters Space Inc. (FJET) is trending as a new low-float aerospace IPO, sparking intense community discussion around a potential short squeeze. Traders are actively debating perceived price manipulation and the high cost to borrow shares, contrasting fundamental concerns with speculative hopes for significant upward moves. This interest is amplified by broader market attention on the space sector, driving highly volatile trading.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax Technologies is trending as Sanofi moves to acquire the company for $15.50 per share in a $2.2 billion deal, significantly expanding Sanofi's vaccine pipeline with DVAX's hepatitis B vaccine and developing shingles treatment. The community is celebrating the premium offered, while also speculating on the strategic value Sanofi may see in DVAX's recent licensing of an oral COVID-19 vaccine program. This acquisition has sparked broader conversations about potential interest in smaller biotech companies within the sector.

Utopia is a digital paradise designed to reward every step of a user's journey. It is a world where community and cutting-edge technology converge to foster unprecedented freedom, creativity, and tangible value.At the heart of Utopia lies a living, breathing ecosystem where user engagement directly fuels the economy.Participants guide the Utopia girl on her path, drawing her closer to the world's core. With each step, a user's influence grows, as do their potential BNB rewards. Utopia is built on the principle that exploration and active participation should be directly linked to prosperity.The path is for each user to shape, and every discovery brings them closer to the center of it all.

Utopia

Utopia Crypto is trending as its recent listing on a major exchange has sparked widespread bullish sentiment within the community. Investors are actively discussing its potential as a "hidden gem" and future powerhouse, driven by its platform focused on in-game token rewards and ongoing development. The strong conviction points to anticipated significant growth.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is trending due to significant insider share accumulation by its CEO, fueling speculation and high retail interest in this low-float Hong Kong-based company. The community is actively debating its extreme volatility and whether it can replicate past parabolic runs seen in similar small-cap plays, despite ongoing discussions about its valuation and business model.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is currently trending following its announced inclusion in the S&P MidCap 400 index, a move expected to generate significant institutional buying pressure and boost market visibility. The community is actively discussing this catalyst as a major inflection point for the pure-play automation leader, anticipating strong long-term growth driven by its Agentic AI solutions and robust financial position. Many investors see this as a key moment, despite some discussions around short-term profit-taking.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is currently trending as its stock experiences a significant decline, sparking intense community debate despite recent bullish partnerships with Meta and Nvidia for AI infrastructure and power-efficient computing. Many question the steep sell-off, attributing it to a recent Goldman Sachs downgrade and perceived market manipulation, while others view the pullback as a prime buying opportunity for a company fundamental to future AI and robotics.

Grayscale Ethereum Trust (ETH) operates as open-end investment company. Its investment objective is for the shares to reflect the value of ETH held by the trust. The company was founded on December 13, 2017 and is headquartered in Stamford, CT.

Grayscale Ethereum Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Ethereum Mini Trust

Grayscale Ethereum Mini Trust is trending as institutional interest in Ethereum surges, with major financial firms like JPMorgan and BlackRock actively integrating the network for tokenized funds and asset accumulation. Community discussions highlight anticipation for the "Fusaka Upgrade" to boost scalability and regulatory clarity around crypto ETPs and staking, reinforcing Ethereum's growing utility as a foundational asset in digital finance.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Kura Oncology is generating significant buzz following the early FDA approval of its lead drug, KOMZIFTI, for relapsed or refractory NPM1-mutated AML, which also triggered a substantial milestone payment from Kyowa Kirin. The community is actively debating KOMZIFTI's perceived superior safety profile and once-daily dosing compared to competitors, fueling strong bullish sentiment around its potential for frontline AML treatment and further data presentations at the upcoming ASH conference. Despite initial 'sell the news' reactions, many investors consider the stock undervalued given its strong financial position and vast market opportunity.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is generating significant buzz as investors eagerly anticipate the imminent FDA decision for its Narsoplimab drug, with the PDUFA date approaching rapidly. The community is highly optimistic for approval, especially given the drug's first-in-class status for an unmet medical need and a recent substantial deal with Novo Nordisk, which many believe sets a higher value floor for the company. Despite recent price volatility and suspected market manipulation by shorts, sentiment remains strong for a transformative approval that could lead to a significant revaluation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
